Reversing cardiac hypertrophy and heart failure using a cardiac targeting peptide linked to miRNA106a.

ABSTRACT:

Background

One in five adults aged 40 will develop heart failure (HF) during their lifetime. Risk factors (e.g., hypertension, diabetes mellitus, coronary artery disease, etc.) lead to structural and functional changes in cardiomyocytes, resulting in HF. At the cellular level, these changes consist of mis/over-expression of genes that regulate cardiac identity (e.g., CamK2δ, PKC, Stat3, etc.). The current paradigm for treating HF is pharmacological or device-based intervention; however, with few exceptions, the condition worsens with time. We are proposing to implement a change in HF treatment, shifting from a drug-centric system to a cardiac target-specific molecular approach that would reverse hypertrophy and adverse remodelling of affected cardiomyocytes.

Methods

A cardio

SUBMITTER: Lu M 

PROVIDER: S-EPMC12358689 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature